TrovaGene, Inc. (TROV) Company Profile
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
News about TROV
The FANG Stocks No Investor Should Miss Right Now
Even at these all-time highs, the FANG stocks are not too pricey. In fact, they're inexpensive. That's the controversial statement Money Morning Chief Investment Strategist Keith Fitz-Gerald made on FOX Business Network's "Varney & Co." ...Read More>>>
ZTE can once again do business with American companies
The United States has officially lifted its crippling export ban on Chinese company ZTE, easing one point of contention with Beijing amid an otherwise escalating trade fight. The US Commerce Department said Friday that it's letting ZTE, which makes ...Read More>>>
How do you rebrand Papa John's when the problem is Papa John?
John Schnatter is Papa John. He's tied to Papa John's advertising as cheese is to pizza, but he resigned as chairman for using a racial slur. How can Papa John's move forward when the guy causing the company's problems is in the commercials and on a...Read More>>>
Wells Fargo's scandals are hurting its bottom line
Wells Fargo's earnings keep getting dinged by a laundry list of scandals. Profit, loans, deposits and revenue all shrank last quarter, Wells Fargo (WFC) said on Friday. One thing that is going up is expenses. Wells Fargo said operating lo...Read More>>>
Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
Acadia Pharmaceuticals (NASDAQ:ACAD) aspires to become a big player in the neuroscience market. Eli Lilly (NYSE:LLY) already is one. But aside from their common interest in this therapeutic category, there's little in common between these two drugmak...Read More>>>